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ABSTRACT  
The incidence of the hematological malignacies, cancers of blood and lymphoid organs, has been in continuous increase for the last 20 years. I n 
Algeria, few data on hematologic malignancies are available in the absence of a population register. The aim of this work is to describe the 
epidemiological aspect of hematologic malignancies in children from northwestern Algeria.  
This study was carried out in 366 patients, with hematological malignancies, aged from 1 month to 15 years, over a period of 5 years (2009-
2013). The study was carried out in the Anti-Cancerous Centre of Oran, Algeria. 
We noted a predominance of male gender comparing to the females with a sex ratio M/F of 1.2. A male predominance was found fo r all 
pathologies (sex ratio of 1.08 for acute lymphoid leukemia, ALL) except for acute myeloid leukemia, AML where a female predominance was 
observed with a sex ratio F/M of 1.21. 0-3 years age group is the most affected by these haemopathies with 34.2%, however, patients older than 
10 years are the least affected. The most frequent malignant haemopathies was the ALL with 60.9%, followed by the AML with 16.9%. The 
mortality rate in all the studied patients is about 8.2%. The mortality rate in patients with chronic myeloid leukemia (CML) was about 20%, 
which is significantly higher compared to those recorded in patients with ALL and LH (5.4% and 5%, respectively).  
This study highlights the need for broader strategies for better understanding of all epidemiological aspects of childhood hematological 
malignancies and for adopting case management and prevention policies. 
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INTRODUCTION 
Hematological malignancies, neoplasms account for about 
40% of cancers in children under the age of 15 years, and 
developed from the bone marrow hematopoietic cells and 
lymphatic system. This kind of hematological malignancy 
develops at the expense of lymphoid lines precursors, with a 
strong preponderance of B-lymphoid line.1 
Leukemia is the most prevalent pediatric cancer. The acute 
lymphoid leukemia (ALL) accounts for about 80% of the 
cases (75% of them are B-ALL), whereas the acute myeloid 
leukemia (AML), which is traditionally encountered in adults, 
accounts for only 20% of cases.2 Usually, the chronic 
lymphoid leukemia (CLL) is not found in children, however, 
the chronic myeloid leukemia (CML) is extremely rare.3-4 The 
upsurge of Hodgkin's lymphoma (HL) incidence is associated 
with the age of children.5 On the other hand, the non-
Hodgkin's lymphoma (NHL) is very rare before the first year 
of life. The Burkitt lymphomas involving mature B-cells 
represent the half of the NHL and represent the most 
common histological type in children aged 3 to 8 years; 
nonetheless, their impact decreases in older children. The T 
and B lymphoblastic lymphomas represent 17% and 5% of 
cases, respectively.6 
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The ionizing radiation exposure is recognized as the major 
risk factor for malignant hemopathies in children7. However, 
other risk factors are established, such as non-ionizing 
radiation, electromagnetic fields of extremely low frequency 
and exposure to radon.8-9 
The purpose of our retrospective study was to describe the 
epidemiological aspect of malignant hemopathies over a 
period of 5 years (2009-2013) at the level of pediatric 
oncology facility of the Anti-Cancer Centre of Oran (North-
Western Algeria). 
METHODS 
In this descriptive retrospective study, we selected and 
treated the medical records of all patients, of both genders 
and aged from one month to 15 years, admitted to the 
hematological clinic or hospitalized at the pediatric oncology 
department of the Anti-Cancer Centre of Oran (North-
Western Algeria) over a period of five years (2009-2013). 
The inclusion criteria were based on a positive diagnosis of 
malignant homeopathy after cytological and/or histological 
examination. However, clinical hematological manifestations 
and therapeutic aspects were excluded. 
Data were processed and analyzed by SPSS software version 
22.0 ('Statistical package for Social Sciences', IBM 
Corporation, Chicago, IL August 2013) for Windows. For all 
analyzes, a p-value of 0.05 or less was considered significant 
with a confidence interval of 95%. The Chi-square test was 
used to compare the values expressed in frequency (%). The 
relationships between the different parameters were studied 
using Pearson's correlation test and the simple linear 
regression test with a 95% confidence interval (CI 95%). 
RESULTS 
A total of three hundred sixty-six (366) patients, aged from 
one month to 15 years, were enrolled in this retrospective 
study. We noted a predominance of male gender comparing 
to the females (54.6% vs. 45.4%, respectively) (Table 1), with 
a sex ratio M/F of 1.2.  
As described in figure 1, male predominance was found for 
all pathologies (e.g. sex ratio M/F of 1.08 for ALL) except for 
acute myeloid leukemia (AML) where a female 
predominance was observed (34 girls against 28 boys with a 
sex ratio F/M of 1.21). 
The mean age of all participants was 6.39±4.33 years (76.72± 
52.05 month) (Table 2). The highest prevalence of the 
studied pathologies was recorded in the age group of 0-3 
years with 34.2%, followed by the age group of 4-6 years 
with 24.3%. However, the prevalence in the age groups of 
10-12 and 13-15 years was 12.0% and 13.9%, respectively. 
The majority of malignant hemopathies were observed 
before the age of 3 years (38.1% of ALL). Though, the 
frequency of HL increases in children after the age of 4 years 
(Table 3) and (Figure 2). 
The most frequent malignant hemopathies was the ALLs 
with 60.9%, followed by the AML with 16.9%. In 
contrariwise, low prevalence was observed of CML and NHL 
with 2.7% and 8.5%, respectively (Table 4). 
Using the Pearson correlation test, positive no significant 
association was noted (r2=0.006, p=0.139) between the age 
of children and the type of pathology (Table 5 and 6). 
As illustrated in table 7, the annual incidence of malignant 
hemopathies has steadily increased in Oran from 68 cases in 
2009 to 96 cases in 2012. Although, a decrease in the ALLs 
was observed (from 56 cases in 2009 to 35 cases in 2012) 
(Figure 3).  
As summarized in Table 8 and 9, high significant correlation 
(r2=0.091, p˂0.001) was observed between the type of 
pathology and the years of hospitalization of patients.  
Results from our study disclosed a mortality rate of 8.2% in 
the studied population (Table 10). The mortality rate was 
fairly high in patients with AML and CML, with 16.1% and 
20%, respectively. On the other hand, low rates were noted 
in patients with ALL and HL with 5.4% and 5%, respectively 
(Table 11) and (Figure 4). 
As depicted in Table 12 and 13, no significant correlation 
(r2=0.008, p=0.073) was observed between the number of 
deaths and the type of pathology.  
 
 
Table 1: Distribution of patients by gender 
 Effective Percentage% Valid 
Percentage 
Cumulative Percentage 
Valid F 166 45.4 45.4 45.4 
M 200 54.6 54.6 100.0 
Total 366 100.0 100.0  
 
 
Table 2: Distribution of patients by age (by years and months) 
 N Minimum Maximum Median Variance Average Standard Deviation 
Age (year) 366 0.083 15.000 6.00 18.819 6.39367 4.338128 
Age (month) 366 1.00 180.00 72.00 2709.988 76.7240 52.05754 
N valid 
(listwise) 
366       
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Table 3: Distribution of pathologies by ageof patients 
 Type of pathology Total 
ALL AML HL CML NHL 
Age range 
(years) 
Less than 3 
years 
Effective 85 19 7 3 11 125 
% included in  age range (years) 68,0% 15,2% 5,6% 2,4% 8,8% 100,0% 
% included in  type of pathology 38,1% 30,6% 17,5% 30,0% 35,5% 34,2% 
4 to 6 years 
Effective 51 17 12 5 4 89 
% included in  age range (years) 57,3% 19,1% 13,5% 5,6% 4,5% 100,0% 
% included in  type of pathology 22,9% 27,4% 30,0% 50,0% 12,9% 24,3% 
7 to 9 years 
Effective 36 6 9 1 5 57 
% included in  age range (years) 63,2% 10,5% 15,8% 1,8% 8,8% 100,0% 
% included in  type of pathology 16,1% 9,7% 22,5% 10,0% 16,1% 15,6% 
10 to 12 years 
Effective 23 10 5 0 6 44 
% included in  age range (years) 52,3% 22,7% 11,4% 0,0% 13,6% 100,0% 
% included in  type of pathology 10,3% 16,1% 12,5% 0,0% 19,4% 12,0% 
13 years and 
more 
Effective 28 10 7 1 5 51 
% included in  age range (years) 54,9% 19,6% 13,7% 2,0% 9,8% 100,0% 
% included in  type of pathology 12,6% 16,1% 17,5% 10,0% 16,1% 13,9% 
Total 
Effective 223 62 40 10 31 366 
% included in  age range (years) 60,9% 16,9% 10,9% 2,7% 8,5% 100,0% 
% included in  type of pathology 100,0% 100,0% 100,0% 100,0% 100,0% 100,0% 
 
Table 4: Distribution of patients by the type of pathology 
 Effective Percentage% Valid Percentage Cumulative Percentage 
Valid ALL 223 60.9 60.9 60.9 
AML 62 16.9 16.9 77.9 
HL 40 10.9 10.9 88.8 
CML 10 2.7 2.7 91.5 
NHL 31 8.5 8.5 100.0 
Total 366 100.0 100.0  
 
Table 5: Relationship between type of pathology and age 
Correlations (Coefficient of correlation r=0.077) 
 Type of pathology Age Group (years) 
Correlation of Pearson Type of pathology 1.000 0.077 
age range (years) 0.077 1.000 
Sig. (unilateral) Type of pathology . 0.070 
age range (years) 0.070 . 
N Type of pathology 366 366 
age range  (years) 366 366 
 
Bachir Bouiadjra et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2020; 10(4):168-174 
ISSN: 2250-1177                                                                                        [171]                                                                                    CODEN (USA): JDDTAO 
Table 6: Meaning test (Fisher Report) 
ANOVAa(Fisher test F=2.198,p=0.139) 
Model Sum of 
squares 
dOF Average of 
squares 
D Sig. 
1 Regression 3.412 1 3.412 2.198 0.139b 
Residue 565.200 364 1.553   
Total 568.612 365    
a. dependent Variable : Type ofpathology 
b. predicted Values : (constants), age range (years) 
 
Table 7: Distribution of pathologies by year of recruitment of patients (incidence) 
 Type of pathology Total 
ALL AML HL LMC NHL 
year 
2009 
Effective 56 10 0 0 2 68 
% included in year 82,4% 14,7% 0,0% 0,0% 2,9% 100,0% 
% included in type of pathology 25,1% 16,1% 0,0% 0,0% 6,5% 18,6% 
2010 
Effective 49 8 1 2 0 60 
% included in year 81,7% 13,3% 1,7% 3,3% 0,0% 100,0% 
% included in type of pathology 22,0% 12,9% 2,5% 20,0% 0,0% 16,4% 
2011 
Effective 44 13 3 3 5 68 
% included in year 64,7% 19,1% 4,4% 4,4% 7,4% 100,0% 
% included in type of pathology 19,7% 21,0% 7,5% 30,0% 16,1% 18,6% 
2012 
Effective 35 17 23 2 19 96 
% included in year 36,5% 17,7% 24,0% 2,1% 19,8% 100,0% 
% included in type of pathology 15,7% 27,4% 57,5% 20,0% 61,3% 26,2% 
2013 
Effective 39 14 13 3 5 74 
% included in year 52,7% 18,9% 17,6% 4,1% 6,8% 100,0% 
% included in type of pathology 17,5% 22,6% 32,5% 30,0% 16,1% 20,2% 
Total 
Effective 223 62 40 10 31 366 
% included in year 60,9% 16,9% 10,9% 2,7% 8,5% 100,0% 
% included in type of pathology 100,0% 100,0% 100,0% 100,0% 100,0% 100,0% 
 
Table 8: Relationship between type of pathology and year of recruitment 
Correlation (Coefficient of correlation r=0.301) 
 Type of pathology Year 
Correlation of Pearson Type of pathology 1.000 0.301 
Year 0.301 1.000 
Sig. (unilateral) Type of pathology . 0.000 
Year 0.000 . 
N Type of pathology 366 366 
Year 366 366 
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Table 9: Meaning test (Fisher Report) 
ANOVAa(Fisher report F=36.221, p<0.001) 
Model Sum of squares dOF Average 
squares 
F Sig. 
1 Regression 51.460 1 51.460 36.221 0.000b 
Residue 517.152 364 1.421   
Total 568.612 365    
a. dependent Variable : Type of pathology 
b. predicted Values : (constants), Year 
 
Tableau 10 : Mortality rate in patients with haematological malignancies 
 Effective Percentage% valid Percentage cumulative 
Percentage 
Valid 
deceased 30 8.2 8.2 8.2 
not deceased 336 91.8 91.8 100.0 
Total 366 100.0 100.0  
 
Table 11: Mortality rate for all haematological malignancies 
 Type of pathology Total 
ALL AML HL CML NHL 
Death 
DCD 
Effective 12 10 2 2 4 30 
% included in Death 40,0% 33,3% 6,7% 6,7% 13,3% 100,0% 
% includedinType of pathology 5,4% 16,1% 5,0% 20,0% 12,9% 8,2% 
NDC 
Effective 211 52 38 8 27 336 
% included in Death 62,8% 15,5% 11,3% 2,4% 8,0% 100,0% 
% included inType of pathology 94,6% 83,9% 95,0% 80,0% 87,1% 91,8% 
Total 
Effective 223 62 40 10 31 366 
% included in Death 60,9% 16,9% 10,9% 2,7% 8,5% 100,0% 
% included inType of pathology 100,0% 100,0% 100,0% 100,0% 100,0% 100,0% 
 
 
Table 12: Relationship between mortality and type of pathology 
Correlation (Coefficient of correlation r=-0.094) 
 Death Type ofpathology 
Correlation of Pearson 
Death 1.000 -.094 
Type of pathology -.094 1.000 
Sig. (unilateral) 
Death . 0.037 
Type of pathology 0.037 . 
N 
Death 366 366 
Type of pathology 366 366 
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Tableau 13: Meaning test (Fisher Report) 
ANOVAa(Fisher test F=3.231, p=0.073) 
Model Sum of squares dOF Average squares F Sig. 
1 
Regression 0.242 1 0.242 3.231 0.073b 
Residue 27.299 364 0.075   
Total 27.541 365    
a. Dependent variable : Death       b. Predicted values: (constant), Type of pathology 
 
 
ALL: Acute Leukemia Lymphoid     AML: Acute Myeloid Leukemia    
HL: Hodgkin's lymphoma     CML: Chronic Myeloid Leukemia       
NHL: Non-Hodgkin's lymphoma 
Figure 1: Average age of patients by type of pathology and 
gender 
 
 
ALL: Acute Leukemia Lymphoid    AML: Acute Myeloid Leukemia      
HL: Hodgkin's lymphoma                 CML: Chronic Myeloid Leukemia   
NHL: Non-Hodgkin's lymphoma 
Figure 2: Distribution of pathologies according to the age of 
patients 
 
ALL: Acute Leukemia Lymphoid       AML: Acute Myeloid Leukemia        
HL: Hodgkin's lymphoma                    CML: Chronic Myeloid Leukemia          
NHL: Non-Hodgkin's lymphoma 
Figure 3: Distribution of pathologies according to the year of 
recruitment 
 
 
ALL: Acute Leukemia Lymphoid        AML: Acute Myeloid Leukemia            
HL: Hodgkin's lymphoma                     CML: Chronic Myeloid Leukemia           
NHL: Non-Hodgkin's lymphoma 
Figure 4: Mortality rates for all haematological malignancies 
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DISCUSSION 
In this retrospective epidemiological study, we aimed to 
describe the epidemiological aspect of malignant 
hemopathies in children aged 1 month to 15 years. The study 
was carried out over a period of 5 years (2009-2013) at the 
level of the pediatric oncology facility of the Anti-Cancer 
Centre of Oran (North-Western Algeria). To the best of our 
knowledge, this investigation is the first to describe the 
malignant hemopathies characteristics in this health facility. 
The outcomes of the current study revealed an increased 
incidence of the malignant hemopathies during the last 
decade in the Northwestern region of Algeria (Wilaya of 
Oran). Similar conclusions were reported from two studies 
carried out in Abidjan between 1995 and 2004 and from the 
United States.10, 11 Likewise, an upsurge in the incidence of 
these pathologies has been shown by the European data of 
ACCIS (Automated Childhood Cancer Information System).12 
The sex ratio M/F in our study was 1.2. This finding matches 
the results obtained in France by Desandes et al. in 2004 (sex 
ratio M/F between 1 and 1.4).13 Similarly, Lahlou et al. in 
Morocco reported a male gender predominance in ALL 
patients with a higher sex ratio (1.32).14 Several authors 
highlighted the higher prevalence of AML in male subjects, 
which is inconsistent with the results of our study. 15-16 The 
association between the female gender and the risk of AML 
must be further explored in order to better understand this 
complication. 
Malignant hemopathies represent about 40% of all cancers 
before the age of 15 years. 34.2% of malignant hemopathies 
were observed before the age of 3 years, these findings are in 
agreement with the results of a European study carried out 
by Clavel et al. where a higher incidence of malignant 
hemopathies was recorded in children under 5 years of age 
during.16 According to Goubin et al., 80% of cases of 
childhood leukemia are acute lymphoblastic leukemia (ALL). 
This complication could occur at any age, and more 
particularly between the 1st and 10th years of life. The higher 
incidence has been reported between 2 and 3 years.17 In our 
study, the highest incidence was observed between 0-3 
years. The incidence of acute myeloid leukemia (AML) is 
higher in children less than 3 years of age and then decreases 
markedly. This decrease can be explained by the fact that 
LAM is more frequent in adults.18 Few cases of Hodgkin's 
lymphoma (HL) were noted in our studied population before 
the age of 4 years, this could be explained by the fact that this 
disease increases with age.19 Chronic lymphocytic leukemia 
(CLL) is not found in children and chronic myeloid leukemia 
(CML) are extremely rare, as these two pathologies mainly 
affect the elderly.20, 21 
Some studies have been devoted to evaluate the malignant 
hemopathies’ mortality in Algeria and Africa. Despite the 
improved diagnosis and therapeutic progress made during 
the last few decades, malignant hemopathies’ mortality 
remains relatively high. In the area of Sidi-Bel-Abbes (North-
Western Algeria), the mortality rate was about 8.2%. This 
frequency might be explained by the lack of diagnostic tools 
at the hematology department and the consultation delays. 
However, any disease prognosis depends on the precocity 
and the accessibility to medical care. One limitation of the 
present study is the retrospective aspect that does not allow 
optimizing the collection of some information in when 
medical records are not standardized. 
 
 
CONCLUSION 
The childhood malignant homeopathies have particular 
epidemiological characteristics in the region of Oran (North-
Western Algeria). Our results highlighted a mortality rate 
that remains not negligible. More strategies involving further 
aspects and policies and based on patient information, public 
awareness and training of medical personnel are needed to 
help reduce the consultation time and better managing and 
preventing malignant homeopathies. 
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